Gelteq Limited reported that its proprietary gel‑based delivery platform achieved a 300 % increase in first‑hour bioavailability and a 20 % improvement in overall absorption over 24 hours for an oil‑soluble compound in two complementary preclinical studies. The data, released on December 5 2025, indicate a faster onset of action and higher total exposure compared with an existing FDA‑approved reference product.
The platform’s gel matrix disperses the active ingredient uniformly along the small intestine, enhancing mucoadhesive interactions and expanding the intestinal surface area for absorption. By reducing reliance on emulsifiers, the gel provides controlled transit and targeted release, a feature that could be applied to a wide range of lipophilic drugs.
Gelteq’s technology is not limited to oil‑soluble compounds. A prior November 24 2025 study showed a 38‑45 % increase in systemic exposure for a water‑soluble antihistamine, underscoring the platform’s versatility. The company’s strategy of partnering with pharmaceutical and nutraceutical firms to reformulate existing assets is reinforced by these results, which could revive shelved candidates and accelerate development in neurology, pain management, cardiovascular medicine, veterinary health, and other therapeutic areas.
The company has already begun commercializing the gel in the U.S. nutraceutical market through Healthy Extracts, Inc., and signed a product development agreement with Melbourne Health for a bowel polyp growth reduction compound. These moves signal a transition from preclinical research to market‑ready applications, while the platform’s broad applicability keeps the company attractive to potential collaborators.
Gelteq is a small‑cap, clinical‑stage company that has reported ongoing losses and funding needs. The preclinical milestone, however, provides a tangible proof of concept that could support future financing rounds and revenue generation. CEO Nathan Givoni described the results as a “major technical and commercial milestone,” highlighting the platform’s potential to transform drug delivery.
Investors responded positively to the announcement, reflecting confidence in the platform’s promise. The data remain preclinical, and further validation in human trials will be required before commercial impact can be realized.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.